3',4'-Anhydrovinblastine

Molecular Formula: C₄₆H₅₆N₄O₈
Molar mass: 792.9588 g/mol
Density: 1.67
Index of Refraction: 1.67
Structure of Anhydrovinblastine (38390-45-3):
                    
XLogP3-AA: 4
H-Bond Donor: 2
H-Bond Acceptor: 11
Canonical SMILES: CCC1=CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC
Isomeric SMILES: CCC1=C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]
78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC
InChI: InChI=1S/C46H56N4O8/c1-8-28-21-29-24-45(41(52)56-6,
37-31(15-19-49(25-28)26-29)30-13-10-11-14-34(30)47-37)33-22-32-35(23-36
(33)55-5)48(4)39-44(32)17-20-50-18-12-16-43(9-2,38(44)50)40(58-27(3)51)46(39,54)42(53)57-7/h10-14,16,21-23,29,38-40,47,54H,8-9,15,17-20,24-26H2,1-7H3/t29-,38+,39-,40-,43-,44-,45+,46+/m1/s1 
InChIKey: FFRFGVHNKJYNOV-DOVUUNBWSA-N

Anhydrovinblastine (38390-45-3) was first synthetized by Rusching in 1969, and brought to the market in Germany by Hoechst AG under the brand name Ultracain.In 1983 it was brought into the North American market, to Canada, under the name Ultracaine for dental use. This brand is currently manufactured in Germany by Sanofi-Aventis and distributed in North America by Hansamed Limited(since 1999).It was approved by the FDA in April 2000, and became available in the United States of America two months later under the brand name Septocaine with Epinephrine 1:100,000 (Septodont).Articadent became available in the United States in October of 2010.Articaine is currently available for the North American dental market.

Anhydrovinblastine (38390-45-3) , also can be called for 3',4'-Anhydrovinblastine ; 3',4'-Didehydro-4'-deoxyvincaleukoblastine ; 3',4'-Dehydroisoleurosine , is a dental local anesthetic. It is the most widely used local anesthetic in a number of European countries and is available in many countries around the world. Anhydrovinblastine (38390-45-3), In dentistry, is used both for infiltration and block injections. And it is used for pain control.
It is not contraindicated in patients with sulfa allergies; there is no cross-allergenicity between articaine's sulfer-bearing thiophene ring and sulfonamides.